Saturday, July 20, 2019

New Models and Approaches to Condition Management Leading to Accelerated Growth of Solutions

New Chilmark Research report assesses maturity of solution features, sets forth rationale for rapid growth. Key healthcare stakeholders are accelerating the adoption of more personalized and holistic approaches to chronic condition management, driven by...

Prime Therapeutics Signs CareCentered Contract™ with leading manufacturer of MS drugs

Contract measures adherence, helps link price of therapy to clinical value Given the growing use and cost of multiple sclerosis (MS) medicines, Prime Therapeutics LLC (Prime), a leading pharmacy benefit manager (PBM), and Biogen,...

Edinburgh Molecular Imaging Commences Phase II European Cancer Trial

Novel Compound with Potential for Early Detection and to Guide Treatment of Colorectal Cancer Edinburgh Molecular Imaging (EM Imaging), the clinical phase biotechnology company focused on enabling image-guided therapy, announces it has commenced a...

The Menarini Group Announced Marketing Authorization Application for Delafloxacin

The Menarini Group announced today that on March 6th 2017 it submitted a Marketing Authorization Application for delafloxacin at the European Medicines Agency (EMA) under the trade name Quofenix. The proposed indication for delafloxacin in Europe is the...

Connect with us

4,475FansLike
1,007FollowersFollow
12,053FollowersFollow

Popular Posts